Issue
Number 322 July 8, 2002
CONTENTS OF THIS ISSUE
- CDC publishes notice
on new acellular pertussis vaccine
- New Influenza
Vaccine Information Statement is now available
- Dr. Julie Gerberding
to head CDC
- New! Four more
comprehensive Disease/Vaccine Information pages
on IAC's website
- Going, going, but
not gone! Popular "Immunization Techniques"
video can still be ordered
- CMS
satellite broadcast on vaccinating nursing home
residents will take place August 16
- APHA annual meeting
and exposition is scheduled for November 9-13
- Reminder: HFI hosts
Hepatitis Summit July 18-19
----------------------------------------------------------
Back to Top
(1 of 8)
July 8, 2002
CDC PUBLISHES NOTICE ON NEW ACELLULAR PERTUSSIS VACCINE
On July 5, 2002, the Centers for Disease Control and Prevention (CDC) published "Notice to Readers: Food and Drug Administration Approval of a
Fifth Acellular Pertussis Vaccine for Use Among
Infants and Young
Children--United States, 2002" in the Morbidity and
Mortality Weekly Report (MMWR).
The Notice reads in part as follows (excluding footnotes):
*******************************
On May 14, 2002, the Food and Drug Administration (FDA)
approved for use an additional combined
diphtheria and tetanus toxoids and acellular
pertussis vaccine (DTaP) (DAPTACEL [TM] Aventis
Pasteur, Ltd. [Toronto, Ontario]) for the
first 4 doses of the diphtheria and tetanus
toxoids and pertussis vaccination (DTP) series
administered to infants and children aged 6 weeks-6 years
(before seventh birthday). DAPTACEL
is the fifth acellular pertussis vaccine to be
licensed for use among infants and young children
in the United States. Of these five, three (Tripedia[R],
Infanrix[TM], and DAPTACEL[TM]) are
distributed in the United States.
DAPTACEL is approved for administration as a 4-dose series
at ages 2, 4, 6, and 17-20 months. The
Advisory Committee on Immunization Practices (ACIP),
the Committee on Infectious Diseases, the
American Academy of Pediatrics, and the
American Academy of Family Physicians recommend
that children routinely receive a series of 5
doses of vaccine against diphtheria, tetanus, and
pertussis before age 7 years. The
first 4 doses should be administered at ages 2, 4,
6, and 15-18 months and the fifth dose at age 4-6
years. The customary age for the first dose is 2
months, but it may be given as early as
age 6 weeks and up to the seventh birthday. The interval
between the third and the fourth dose
should be at least 6 months. Data are insufficient
to evaluate the use of DAPTACEL as a fifth dose
among children aged 4-6 years who have
received DAPTACEL for the previous 4 doses. DAPTACEL
may be used to complete the vaccination series in infants
who have received 1 or more doses of whole-cell pertussis
DTP. . . .
Whenever feasible, the same DTaP vaccine should be used
throughout the entire vaccination series.
Data are limited on the safety, immunogenicity, or
efficacy of different DTaP vaccines when
administered interchangeably in the primary
or booster vaccination of a child. However, if the
vaccine provider does not know or have
available the type of DTaP vaccine the child to be
vaccinated had received
previously, any of the licensed DTaP vaccines may be used
to complete the vaccination series.
*******************************
To obtain the complete text of the Notice online, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5126a5.htm
To obtain a camera-ready (PDF format) copy of this issue of MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5126.pdf
HOW TO OBTAIN A FREE ELECTRONIC SUBSCRIPTION TO THE MMWR:
To obtain a free electronic subscription to the "Morbidity and Mortality
Weekly Report" (MMWR), visit CDC's MMWR website
at: http://www.cdc.gov/mmwr
Select "Free MMWR Subscription" from the
menu at the left of the screen. Once you have submitted the required
information, weekly issues of the MMWR and all new
ACIP statements (published as MMWR's "Recommendations and Reports") will
arrive automatically by email.
----------------------------------------------------------
Back to Top
(2 of 8)
July 8, 2002
NEW INFLUENZA VACCINE INFORMATION STATEMENT IS NOW
AVAILABLE
The Centers for Disease Control and Prevention (CDC) has
issued a new Influenza Vaccine Information
Statement (VIS) for 2002-2003. Dated 6/26/02, the
new "flu VIS" features significant changes from
the 2001-2002 version.
Of special note are changes in the sections "Who should
get influenza vaccine?" and "When should I
get influenza vaccine?" These and other sections
reflect new recommendations as outlined in the
April 12, 2002,
statement from the Advisory Committee on Immunization
Practices (ACIP), "Prevention and Control
of Influenza" (MMWR; vol. 51, no. RR-3).
Don't forget that an annual flu shot is now encouraged for
healthy children 6-23 months of age, when
feasible, and their household contacts and
out-of-home caretakers, as well as household
contacts and out-of-home caretakers of
infants less than 6 months of age.
To obtain a copy of the Influenza VIS in camera-ready
(PDF) format, use either of the two following
links:
CDC:
http://www.cdc.gov/nip/publications/VIS/vis-flu.pdf
IAC:
http://www.immunize.org/vis/2flu.pdf
To obtain copies of all other VISs, including some in up
to 27 languages, visit IAC's website at:
http://www.immunize.org/vis/
IAC's website also has links to CDC instructions on how to
use VISs and their legal requirements. For
"Vaccine Information Statements: What You Need to
Know," go to:
http://www.immunize.org/vis/instr01.htm
For "Instructions for Use of Vaccine Information
Statements," go to:
http://www.immunize.org/vis/instr2.pdf
----------------------------------------------------------
Back to Top
(3 of 8)
July 8, 2002
DR. JULIE GERBERDING TO HEAD CDC
On Wednesday, July 3, 2002, the U.S. Department of Health
and Human Services announced the
appointment of Julie L. Gerberding, M.D., M.P.H.,
as Director of the Centers for Disease Control and
Prevention (CDC). The full announcement
reads as follows:
******************************
HHS Secretary Tommy G. Thompson today named Julie L.
Gerberding, M.D., M.P.H., to be director of
the Centers for Disease Control and Prevention
(CDC) and administrator for the Agency for Toxic
Substances and Disease Registry (ATSDR).
Dr. Gerberding is an infectious disease expert and
has been leading CDC's efforts to prepare for and
counterterrorism. She assumes the post immediately.
Dr. Gerberding, 46, has been acting principal deputy
director of CDC, and has served as part of the
leadership team named to direct the agency
since former director Dr. Jeffrey Koplan resigned
March 31. She has also served as
acting deputy director of CDC's National Center for
Infectious Diseases.
"Dr. Gerberding knows public health, she knows infectious
diseases, and she knows bioterrorism
preparedness," Secretary Thompson said. "She
brings the right mix of professional experience
and leadership skills to ensure
the CDC continues to meet the nation's public health needs."
Dr. Gerberding played a major role in leading CDC's
response to the anthrax bioterrorism attacks last fall.
"The events of last fall made clear to all of us that this
cannot be a time of business-as-usual," Dr.
Gerberding said. "In a time of rapid change and
growing responsibilities, CDC will ensure
excellence in public
health science, excellence in service to our public health
partners and a sound organizational system
to ensure that we fulfill our mission."
Dr. Gerberding joined the CDC in 1998 as director of the
Division of Healthcare Quality Promotion,
where she developed CDC's patient safety
initiatives and other programs to prevent
infections, antimicrobial resistance
and medical errors in healthcare settings. Previously, she
headed the Prevention Epicenter--a
multidisciplinary service, teaching, and research
program that focused on preventing infections in
patients and their healthcare providers at the
University of California, San Francisco (UCSF).
Dr. Gerberding earned her B.A. degree in chemistry and
biology and M.D. degree at Case Western
Reserve University in Cleveland, Ohio. She
completed her internship and residency in internal
medicine at UCSF, where she also
served as chief medical resident at San Francisco General
Hospital before completing her
National Institutes of Health (NIH) training
fellowship in clinical pharmacology and
infectious diseases at UCSF. She earned her Masters of
Public Health (MPH) degree at the University
of California, Berkeley, in 1990.
Dr. Gerberding is also a tenured associate professor of
medicine and epidemiology and biostatistics at
UCSF and an associate clinical professor of
medicine at Emory University.
She is a native of South Dakota and is married to David A.
Rose.
Secretary Thompson also praised the interim leadership
team that steered CDC during the past three
months. "During these months, the CDC remained
focused on its essential missions, including an
unprecedented rapid review of state
bioterrorism preparedness plans required in
issuing some $1.1 billion in grants to states," he
said. "David Fleming and the other members of the interim
team all deserve credit for making
the transition a smooth one."
The CDC is the nation's disease prevention agency,
protecting people's health and safety, providing
credible information to enhance health decisions,
and improving health through strong partnerships.
The agency includes 11
institutes, centers and offices, with nearly 8,600
employees. Its fiscal year 2002 budget is $6.8
billion.
******************************
----------------------------------------------------------
Back to Top
(4 of 8)
July 8, 2002
NEW! FOUR MORE COMPREHENSIVE DISEASE INFORMATION PAGES ON
IAC'S WEBSITE
The "Diseases/Vaccines" section of IAC's website now
contains individual web pages for 11 different
diseases and the vaccines that prevent
them. Links to all of these pages appear on the
lefthand index bar on our home page.
The newest additions to this section are: the
Hepatitis A Information page, the Haemophilus
influenzae type b (Hib)
Information page, the Influenza Information page, and the
Polio Information page.
You will find these Disease/Vaccine Information pages very
useful the next time you need answers to
questions about outbreaks, vaccine
recommendations, vaccine efficacy, state laws,
case histories, and other issues.
To view IAC's Hepatitis A Information page, go to:
http://www.immunize.org/hepa
To view IAC's Hib Information page, go to:
http://www.immunize.org/hib
To view IAC's Influenza Information page, go to:
http://www.immunize.org/influenza
To view IAC's Polio Information page, go to:
http://www.immunize.org/polio
----------------------------------------------------------
Back to Top
(5 of 8)
July 8, 2002
GOING, GOING, BUT NOT GONE! POPULAR "IMMUNIZATION
TECHNIQUES" VIDEO CAN STILL BE ORDERED
Since we first offered the video "Immunization Techniques:
Safe, Effective, Caring" in IAC EXPRESS
#273 in September 2001, IAC has sold more than
4,000 videotapes! Don't be the last immunization
provider on your block to buy and show
"Immunization Techniques"! Because this video was so
well-received as a staff training tool and refresher
course, we are announcing it once again as follows:
Every clinic in the United States that delivers
vaccination services should have a copy of the 35-minute
video titled "Immunization Techniques: Safe, Effective,
Caring." Developed by the California Department
of Health Services Immunization Branch in
collaboration with a team of national experts,
this video teaches best practices
about how to administer intramuscular (IM) and
subcutaneous (SC) vaccines to infants,
children, and adults. It is designed for use as a
"hands-on" instructional program for new staff
as well as a refresher course for
experienced health professionals.
The video provides discussion of all the following:
Anatomic sites
Choice of needle size
Vaccines and routes of administration
How to "draw up" doses of vaccine from a vial
Infants, toddlers, kindergartners, and adults are
vaccinated in the video to demonstrate these techniques.
The video comes with presenter's notes that include
instructional objectives, pre- and post-tests,
photos showing vaccination sites
appropriate for infants and toddlers, and a skills
checklist to help you document
that your staff is well trained.
IAC distributes the video and presenter's notes at $15 per
set (to U.S. addresses). California Distance
Learning Health Network (CDLHN) offers it
at $25 per set. The versions are the same except
that IAC's video comes in a
plain cardboard sleeve and the presenter's notes are
printed in black and white, while CDLHN's
video box and presenter's notes are printed in
color. The videotape and text of presenter's
notes are identical. CDLHN also has a
Spanish version available.
Order online (U.S. addresses only) at:
https://www.immunize.org/iztech
Alternatively, an IAC order form is available at:
http://www.immunize.org/catg.d/2020a.pdf
Send your order payment (check, credit card information,
or purchase order) to Immunization Action
Coalition, 1573 Selby Ave., Ste. 234, St. Paul, MN
55104 and include your complete mailing
information and phone number. You can fax
your order with payment information to IAC at (651) 647-9131. If you
are placing an order from outside the United
States, please call IAC at (651) 647-9009 for pricing
information.
To order through CDLHN, call (619) 594-3348, email
cdlhn@projects.sdsu.edu,
or visit CDLHN online at
http://www.cdlhn.com/
----------------------------------------------------------
Back to Top
(6 of 8)
July 8, 2002
CMS SATELLITE BROADCAST ON VACCINATING NURSING HOME
RESIDENTS WILL TAKE PLACE AUGUST 16
The Centers for Medicare and Medicaid Services (CMS) will
broadcast and webcast the program "New
Interpretive Guidelines for Vaccinating Nursing
Home Residents" on Friday, August 16, 2002, 1:00
p.m. to 3:30 p.m. EST.
The targeted audience for this free program includes
nursing home administrators, nursing home
surveyors, medical directors, and nurses. The
program may also benefit nurse practitioners,
infection control
practitioners, epidemiologists, physicians, physician
assistants, and nursing home inspection personnel.
The educational program will be a mix of live discussion,
pre-taped video, graphs, and data. A live
question-and-answer session will be held with the moderator and panel.
For details on the satellite broadcast or internet access
to the webcast, go to:
http://www.cms.hhs.gov/medlearn/broadcst.asp
If you have further questions, contact Jackie Harley by
phone at (410) 786-7222 or email at
jharley@cms.hhs.gov
----------------------------------------------------------
Back to Top
(7 of 8)
July 8, 2002
APHA ANNUAL MEETING AND EXPOSITION IS SCHEDULED FOR
NOVEMBER 9-13
Early-bird registration ends August 30 for the 130th
American Public Health Association (APHA) Annual
Meeting and Exposition scheduled for
November 9-13, 2002, in Philadelphia,
Pennsylvania.
APHA members and others can save up to $50 by registering
during the summer months.
More than 4,000 papers will be presented at the APHA
meeting, and more than 600 booths will be
geared toward public health professionals in the
exhibition areas.
To read about the meeting and hotel accommodations and to
register online, go to:
http://www.apha.org/meetings
If you have questions, contact APHA by phone at (202) 777-2742 or contact
Laser Registration by phone at (514) 228-3009
(Canadian number) or email at
apha@laser-registration.com
----------------------------------------------------------
Back to Top
(8 of 8)
July 8, 2002
REMINDER: HFI HOSTS HEPATITIS SUMMIT JULY 18-19
The Hepatitis Foundation International (HFI) is hosting
this 2-day education and training conference for
health providers at all levels, as well as
for patient advocates and "all others working with
people who are affected or
infected by hepatitis." The Hepatitis Summit, with the
theme "Viral Hepatitis: An Emerged
Epidemic," will take place July 18 and 19 in La
Mirada, Los Angeles County, California.
Program topics include the epidemiology of viral
hepatitis, sexual transmission and risks, and
managing the coinfected HIV/HCV patient. Experts
in the field of viral hepatitis will be present
from the National
Institutes of Health, the Centers for Disease
Control and Prevention, the Huntington Medical Institutes,
and other organizations. Continuing education credits are
available.
To read about the summit online, go to:
http://www.hepfi.org/pdfs/summitregistration.pdf
For more information, contact HFI by phone at (800) 891-0707.
|
